https://www.tesseratherapeutics.com/news/tessera-therapeutics-appoints-joseph-romanelli-as-president-and-chief-executive-officer2026-07-23T13:02:23-04:00weekly0.5https://www.tesseratherapeutics.com/news/tessera-therapeutics-showcases-new-preclinical-data-advancing-in-vivo-program-in-sickle-cell-disease-and-car-t-applications-at-the-american-society-of-gene-and-cell-therapy-29th-annual-meeting2026-05-14T10:38:16-04:00weekly0.5https://www.tesseratherapeutics.com/news/tessera-therapeutics-to-present-new-preclinical-data-supporting-in-vivo-program-in-sickle-cell-disease-and-advancements-in-in-vivo-car-t-applications-at-the-american-society-of-gene-and-cell-therapy-29th-annual-meeting2026-04-27T16:58:03-04:00weekly0.5https://www.tesseratherapeutics.com/news/tessera-therapeutics-receives-grant-to-advance-in-vivo-gene-writing-approaches-towards-a-potential-human-immunodeficiency-virus-hiv-cure2026-03-30T15:02:17-04:00weekly0.5https://www.tesseratherapeutics.com/news/tessera-therapeutics-receives-u-s-fda-fast-track-and-orphan-drug-designations-for-its-lead-in-vivo-gene-editing-program-tsra-196-for-the-treatment-of-adults-with-aatd2026-02-23T07:15:25-05:00weekly0.5https://www.tesseratherapeutics.com/news/tessera-therapeutics-announces-fda-clearance-of-ind-application-for-its-lead-in-vivo-gene-editing-program-tsra-196-for-aatd2026-03-30T15:01:28-04:00weekly0.5https://www.tesseratherapeutics.com/news/tessera-therapeutics-announces-chief-financial-officer-cfo-transition-and-appointment-of-kathy-bergsteinsson-as-cfo2026-03-30T15:05:56-04:00weekly0.5https://www.tesseratherapeutics.com/news/tessera-therapeutics-showcases-new-preclinical-data-demonstrating-progress-of-in-vivo-programs-for-sickle-cell-disease-and-t-cell-therapies-at-the-67th-american-society-of-hematology-annual-meeting2026-04-30T09:58:39-04:00weekly0.5https://www.tesseratherapeutics.com/news/regeneron-and-tessera-therapeutics-to-jointly-develop-tsra-196-an-investigational-gene-editing-therapy-for-alpha-1-antitrypsin-deficiency-aatd2026-03-30T15:06:40-04:00weekly0.5https://www.tesseratherapeutics.com/news/tessera-therapeutics-to-present-new-preclinical-data-from-in-vivo-programs-for-sickle-cell-disease-and-t-cell-therapies-at-the-67th-american-society-of-hematology-annual-meeting2026-03-30T15:07:32-04:00weekly0.5https://www.tesseratherapeutics.com/news/tessera-therapeutics-awarded-up-to-41-3-million-from-arpa-h-to-advance-in-vivo-car-t-therapies2025-10-08T11:33:37-04:00weekly0.5